Loading...
•
Dec 31, 2024
Concentra Group Holdings Q4 2024 Earnings Report
Estimated Revenue:$461M
Estimated EPS:$0.159
Key Takeaways
Concentra reported preliminary unaudited financial results for Q4 2024, with revenue increasing by 5.5% over Q4 2023 and Adjusted EBITDA increasing by 13.6%. The company also announced a definitive agreement to acquire Nova Medical Centers and provided its preliminary 2025 business outlook.
Revenue for Q4 2024 increased by 5.5% to $465.0 million compared to Q4 2023.
Adjusted EBITDA for Q4 2024 increased by 13.6% to $77.5 million compared to Q4 2023.
Net income for Q4 2024 was in the range of $20.6 million to $22.6 million, a decrease from $28.9 million in Q4 2023.
Patient Visits per Day decreased by 2.1% from Q4 2023, while Revenue per Visit increased by 5.8% over Q4 2023.
Forward Guidance
For the full year 2025, giving effect to the acquisition of Nova Medical Centers, Concentra expects revenue of approximately $2.1 billion and Adjusted EBITDA in the range of $410 million to $425 million.
Positive Outlook
- Expected revenue of approximately $2.1 billion for FY 2025.
- Expected Adjusted EBITDA in the range of $410 million to $425 million for FY 2025.
- Expected net leverage ratio of approximately 3.5x for FY 2025.
- Acquisition of Nova Medical Centers expected to expand access and services.
- Continued focus on providing superior outcomes and exceptional experience to patients and customers.
Challenges Ahead
- No specific negative guidance points were provided in the report for 2025.
- Potential risks associated with integrating Nova Medical Centers.
- General market and economic conditions could impact performance.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...